INOVIO Appoints Steven Egge as Chief Commercial Officer Amid Launch Preparations

INOVIO Pharmaceuticals

PLYMOUTH MEETING, PAINOVIO (NASDAQ: INO) has appointed Steven Egge as Chief Commercial Officer. Mr. Egge will spearhead the company’s commercial strategy and operations as it gears up for the potential launch of its first DNA medicine product, INO-3107, targeting recurrent respiratory papillomatosis (RRP).

Dr. Jacqueline Shea, INOVIO’s President and CEO, expressed enthusiasm about the new appointment. “We are delighted to welcome Steve to INOVIO and look forward to adding his expertise to our leadership team as we continue advancing our preparations to commercially launch INO-3107 in 2025, should it receive approval by the FDA as a treatment for RRP,” she said. Dr. Shea highlighted Mr. Egge’s extensive experience in launching new products and driving market share in competitive environments.

Strategic Expertise

Mr. Egge brings a wealth of experience to INOVIO, having held significant roles at Sumitomo Pharma, Merck, and Genfit Corp. At Sumitomo Pharma, he served as Senior Vice President and General Manager for Women’s Health, where he built the commercial leadership team and accelerated the launch of Myfembree®. His tenure at Merck spanned two decades, during which he led Merck’s HPV Vaccines Franchise and served as Chief Marketing Officer for the Vaccine Division. He oversaw numerous key launches, including those for GARDASIL® and GARDASIL9®.

Pivotal Timing

“This is a great time to join INOVIO as the company has the opportunity to market the first therapeutic option for patients suffering from RRP, a rare and debilitating HPV-related disease that significantly impacts quality of life,” said Mr. Egge. He expressed excitement about collaborating with INOVIO’s team to enhance commercial strategies and capabilities.

READ:  Globus Medical Gains FDA Clearance for New Knee Surgery Technology

The appointment of Mr. Egge comes as INOVIO prepares to transition into a commercial-stage company. INO-3107, if approved by the FDA, could become the first therapeutic solution for RRP, a disease with unmet medical needs.

Experienced Leadership

In addition to his roles at Sumitomo Pharma and Merck, Mr. Egge served at Genfit Corp., a French biotech company focused on liver diseases, where he led commercial planning and business development. His extensive background in immunology and vaccines, HPV, and rare diseases positions him well to drive INOVIO’s commercial initiatives.

With Mr. Egge’s appointment, INOVIO aims to strengthen its market presence and effectively launch INO-3107, potentially providing a groundbreaking treatment option for RRP patients.

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and Microsoft Start.